A small group of members met in London to review ongoing projects, consider EU funding opportunities and brainstorm areas where the collaboration would make biggest potential impact. There is much we will achieve as a group which wouldn’t otherwise be possible. Analyses of exposures within rare cancers (and subgroups of common common cancers) will be one of these key areas. There are exciting times ahead as we develop our analysis infrastructure, education/mentioning and are keen to expand the network into new countries. Please contact us if you are interested in participating.
The second face-to-face meeting of the group was held in London on the 13th January 2015. Updates were given on the two initial projects pursued by the group and some preliminary results presented. The main focus of the meeting was on the future of the group and potential funding opportunities and new projects. The next meeting will be scheduled to coincide with an appropriate conference in the region.
The inaugural steering group of the collaboration was held in Dublin on the 24th September 2013. Participants attended from: Belgium, Denmark, Finland, Ireland, Netherlands, Northern Ireland, Scotland and Sweden. The group strategy was defined and common funding opportunities identified. Initials projects for potential collaboration are: Breast cancer and propranolol; Male breast cancer and 5α-reductase inhibitors.
The first Irish Cancer Pharmacoepidemiology Symposium was held in Dublin on the 23rd September 2013. International and Irish speakers were invited to present their research and discuss current trends in Pharmacoepidemiology. Slides from all presentations have been made available.